Bringing Life to PK Profiles

In Vivo-Relevance From an In Vitro Environment

In this webinar, we introduce a new MPS platform designed to address these challenges: the PhysioMimix™ PK – a novel microformulator developed by CN Bio. The original unit was invented by Professor John Wikswo from Vanderbilt University. By delivering dynamic, customized PK profiles for two drugs from human-relevant in vitro biological models, this unique technology provides a means to explore and predict clinically relevant treatment combinations and dosing schedules.

Speaker Information:
Dr Tudor Petreus

Senior Scientist
CN Bio

Watch this webinar to learn:

  • Introduce the working principles and flexibility of the PhysioMimix™ PK
  • Emphasize its capabilities regarding exposure to clinically relevant monotherapies or drug combinations/schedules
  • Demonstrate the PhysioMimix™ PK’s enhanced performance versus classical techniques

In drug development, microphysiological systems (MPS) are utilized to develop in vitro biological models that can generate more physiologically- and human-relevant data.

However, typical step-changes in drug concentrations from in vitro dosing solutions do not adequately reflect in vivo  pharmacokinetic (PK) exposure profiles, potentially resulting in inaccurate ranking of drug effectiveness.

Visit cn-bio.com for more information & news